Navigation Links
Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
Date:3/1/2011

WELLESLEY HILLS, Mass., March 1, 2011 /PRNewswire/ -- Source Precision Medicine, Inc., dba SourceMDx ("SourceMDx") has assigned all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of SourceMDx creditors.

Source MDx® is an industry leader in developing simple blood tests that can consistently detect the presence and aggressiveness of cancer by measuring specific RNA transcripts in blood. RNA is an early biological measure of disease, providing a significant indicator of disease onset or progression in the blood stream before other clinical manifestations become observable. Source MDx® is the first to translate robust RNA-transcript based assays into clinically useful oncology molecular diagnostic tests using a simple, non-invasive blood test. Source MDx® tests are precise and calibrated measurements of white blood cell gene expression and track an individual's current health, disease status and response to therapy in a reproducible fashion.

The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, April 29, 2011 at noon.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@finnwarnkegayton.com or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton  (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX Pharmaceuticals Inc. and NoblePeak Vision Corp.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Resource Available for People With Lymphoma
2. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
3. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
4. Trojan(R) and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health
5. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
6. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
7. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
8. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
9. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
10. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
11. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology:
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):